Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Up 125.0% in February

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 900 shares, a growth of 125.0% from the January 31st total of 400 shares. Based on an average daily volume of 13,500 shares, the short-interest ratio is currently 0.1 days.

Scinai Immunotherapeutics Price Performance

NASDAQ:SCNI opened at $3.54 on Monday. The company has a market cap of $3.02 million, a price-to-earnings ratio of -0.01 and a beta of 2.37. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.16 and a current ratio of 1.16. The stock’s fifty day moving average price is $3.47 and its two-hundred day moving average price is $3.52. Scinai Immunotherapeutics has a 52-week low of $2.23 and a 52-week high of $8.92.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.